Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ANAPTYSBIO, INCANAB · Entity 4640 | CHIEF LEGAL OFFICER | February 11, 2026 | February 13, 2026 |
| OTONOMY, INC.OTIC · Entity 116495 | GC & Chief Compliance Officer | February 01, 2018 | February 05, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ANAPTYSBIO, INC
Report date February 11, 2026 · Filed February 13, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 12,835 |
Ending reported balance
After 2026-02-11 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-02-11 · Exercise / conversion · Acquired 10,000 · Balance 22,835 Row 2 · 2026-02-11 · Sale · Disposed 10,000 · Balance 12,835 F1: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person dated April 11, 2025. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $29.70 · Expires 2031-02-09 | Direct | 35,000 |
Reported balance
After 2026-02-11 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-02-11 · Exercise / conversion · Disposed 10,000 · Balance 35,000 F2: The stock option is fully vested. F3: In addition to the options to purchase a total of 35,000 shares of common stock as set forth in Table II, the Reporting Person also holds additional options to purchase up to an aggregate of 436,010 shares of common stock, which options vest according to their terms. |
Filing footnotes · ownership attribution and instrument terms
F1: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person dated April 11, 2025.
F2: The stock option is fully vested.
F3: In addition to the options to purchase a total of 35,000 shares of common stock as set forth in Table II, the Reporting Person also holds additional options to purchase up to an aggregate of 436,010 shares of common stock, which options vest according to their terms.
OTONOMY, INC.
Report date February 01, 2018 · Filed February 05, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.80 · Expires 2028-01-31 | Direct | 110,000 |
Reported balance
After 2018-02-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-02-01 · Grant · Acquired 110,000 · Balance 110,000 F1: One-fourth (1/4) of the shares subject to the option vest on February 1, 2019 and one forty-eighth (1/48) of the shares vest monthly thereafter. F2: In addition to the options acquired as set forth in Table II, the Reporting Person currently holds options to purchase up to an aggregate of 146,665 shares of common stock, which options vest according to their terms. |
Filing footnotes · ownership attribution and instrument terms
F1: One-fourth (1/4) of the shares subject to the option vest on February 1, 2019 and one forty-eighth (1/48) of the shares vest monthly thereafter.
F2: In addition to the options acquired as set forth in Table II, the Reporting Person currently holds options to purchase up to an aggregate of 146,665 shares of common stock, which options vest according to their terms.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 11, 2026 Filed Feb 13, 2026 16:05 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $29.70 | $0.00 |
DisclosureSEC source: 0001239648-26-000007 · form4-02132026_040201.xml · derivative · entry 3 LOUMEAU ERIC J · CIK 0001239648 · CHIEF LEGAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 10,000 shares Expires 2031-02-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The stock option is fully vested. F3 · balance_after: In addition to the options to purchase a total of 35,000 shares of common stock as set forth in Table II, the Reporting Person also holds additional options to purchase up to an aggregate of 436,010 shares of common stock, which options vest according to their terms. Read SEC document |
| February 11, 2026 Filed Feb 13, 2026 16:05 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | SaleCommon Stock | 10,000 | $54.00 | $540,000.00 |
DisclosureSEC source: 0001239648-26-000007 · form4-02132026_040201.xml · nonDerivative · entry 2 LOUMEAU ERIC J · CIK 0001239648 · CHIEF LEGAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 12,835 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person dated April 11, 2025. Read SEC document |
| February 11, 2026 Filed Feb 13, 2026 16:05 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | Exercise / conversionCommon Stock | 10,000 | $29.70 | $297,000.00 |
DisclosureSEC source: 0001239648-26-000007 · form4-02132026_040201.xml · nonDerivative · entry 1 LOUMEAU ERIC J · CIK 0001239648 · CHIEF LEGAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 22,835 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 08, 2026 Filed Jan 9, 2026 19:13 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | SaleCommon Stock | 2,210 | $44.71 | $98,809.10 |
DisclosureSEC source: 0001239648-26-000006 · form4-01102026_120125.xml · nonDerivative · entry 2 LOUMEAU ERIC J · CIK 0001239648 · CHIEF LEGAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,835 F2 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. Read SEC document |
| January 07, 2026 Filed Jan 8, 2026 16:12 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | SaleCommon Stock | 500 | $47.23 | $23,615.00 |
DisclosureSEC source: 0001239648-26-000004 · form4-01082026_090136.xml · nonDerivative · entry 5 LOUMEAU ERIC J · CIK 0001239648 · CHIEF LEGAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,157 F3 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person dated April 11, 2025. Read SEC document |
| January 07, 2026 Filed Jan 8, 2026 16:12 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | SaleCommon Stock | 1,841 | $46.13 | $84,925.51 |
DisclosureSEC source: 0001239648-26-000004 · form4-01082026_090136.xml · nonDerivative · entry 4 LOUMEAU ERIC J · CIK 0001239648 · CHIEF LEGAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,657 F3 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person dated April 11, 2025. F5 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.96 to $46.83 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 07, 2026 Filed Jan 8, 2026 16:12 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | SaleCommon Stock | 5,281 | $45.38 | $239,672.38 |
DisclosureSEC source: 0001239648-26-000004 · form4-01082026_090136.xml · nonDerivative · entry 3 LOUMEAU ERIC J · CIK 0001239648 · CHIEF LEGAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,498 F3 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person dated April 11, 2025. F4 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.87 to $45.835 per share, inclusive. The reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 07, 2026 Filed Jan 8, 2026 16:12 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | SaleCommon Stock | 2,017 | $45.11 | $90,986.87 |
DisclosureSEC source: 0001239648-26-000004 · form4-01082026_090136.xml · nonDerivative · entry 2 LOUMEAU ERIC J · CIK 0001239648 · CHIEF LEGAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,779 F2 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. Read SEC document |
| January 07, 2026 Filed Jan 9, 2026 19:13 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | Exercise / conversionRestricted Stock Unit · Derivative | 5,888 | $0.00 | $0.00 |
DisclosureSEC source: 0001239648-26-000006 · form4-01102026_120125.xml · derivative · entry 3 LOUMEAU ERIC J · CIK 0001239648 · CHIEF LEGAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,662 Underlying: Common Stock · 5,888 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration. F3 · derivative.exercise_date: The RSUs vests as to 25% of the total RSUs annually commencing on January 7, 2026 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. F3 · derivative.expiration_date: The RSUs vests as to 25% of the total RSUs annually commencing on January 7, 2026 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| January 07, 2026 Filed Jan 9, 2026 19:13 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | Exercise / conversionCommon Stock | 5,888 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001239648-26-000006 · form4-01102026_120125.xml · nonDerivative · entry 1 LOUMEAU ERIC J · CIK 0001239648 · CHIEF LEGAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,045 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration. Read SEC document |
| January 06, 2026 Filed Jan 8, 2026 16:12 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | GrantStock Option (right to buy) · Derivative | 23,200 | $0.00 Strike: $43.91 | $0.00 |
DisclosureSEC source: 0001239648-26-000004 · form4-01082026_090136.xml · derivative · entry 8 LOUMEAU ERIC J · CIK 0001239648 · CHIEF LEGAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,200 Underlying: Common Stock · 23,200 shares Expires 2036-01-05 F8 · derivative.exercise_date: The stock option vests as to 25% of the total shares on January 6, 2027, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| January 06, 2026 Filed Jan 8, 2026 16:12 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | GrantRestricted Stock Unit · Derivative | 17,100 | $0.00 | $0.00 |
DisclosureSEC source: 0001239648-26-000004 · form4-01082026_090136.xml · derivative · entry 7 LOUMEAU ERIC J · CIK 0001239648 · CHIEF LEGAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,100 Underlying: Common Stock · 17,100 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration. F7 · derivative.exercise_date: The RSUs vests as to 25% of the total RSUs annually commencing on January 6, 2027 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. F7 · derivative.expiration_date: The RSUs vests as to 25% of the total RSUs annually commencing on January 6, 2027 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| January 06, 2026 Filed Jan 8, 2026 16:12 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | Exercise / conversionRestricted Stock Unit · Derivative | 5,545 | $0.00 | $0.00 |
DisclosureSEC source: 0001239648-26-000004 · form4-01082026_090136.xml · derivative · entry 6 LOUMEAU ERIC J · CIK 0001239648 · CHIEF LEGAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,545 Underlying: Common Stock · 5,545 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration. F6 · derivative.exercise_date: The RSUs vests as to 25% of the total RSUs annually commencing on January 6, 2024 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. F6 · derivative.expiration_date: The RSUs vests as to 25% of the total RSUs annually commencing on January 6, 2024 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| January 06, 2026 Filed Jan 8, 2026 16:12 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | Exercise / conversionCommon Stock | 5,545 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001239648-26-000004 · form4-01082026_090136.xml · nonDerivative · entry 1 LOUMEAU ERIC J · CIK 0001239648 · CHIEF LEGAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,796 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration. Read SEC document |
| January 05, 2026 Filed Jan 6, 2026 21:03 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | SaleCommon Stock | 2,983 | $43.26 | $129,044.58 |
DisclosureSEC source: 0001239648-26-000002 · form4-01072026_020121.xml · nonDerivative · entry 2 LOUMEAU ERIC J · CIK 0001239648 · CHIEF LEGAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,251 F2 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. Read SEC document |
| January 03, 2026 Filed Jan 6, 2026 21:03 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | Exercise / conversionRestricted Stock Unit · Derivative | 7,287 | $0.00 | $0.00 |
DisclosureSEC source: 0001239648-26-000002 · form4-01072026_020121.xml · derivative · entry 3 LOUMEAU ERIC J · CIK 0001239648 · CHIEF LEGAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,575 Underlying: Common Stock · 7,287 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration. F3 · derivative.exercise_date: The RSUs vests as to 25% of the total RSUs annually commencing on January 3, 2025 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. F3 · derivative.expiration_date: The RSUs vests as to 25% of the total RSUs annually commencing on January 3, 2025 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| January 03, 2026 Filed Jan 6, 2026 21:03 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | Exercise / conversionCommon Stock | 7,287 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001239648-26-000002 · form4-01072026_020121.xml · nonDerivative · entry 1 LOUMEAU ERIC J · CIK 0001239648 · CHIEF LEGAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,234 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration. Read SEC document |
| December 22, 2025 Filed Dec 23, 2025 16:27 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $14.02 | $0.00 |
DisclosureSEC source: 0001239648-25-000006 · form4-12232025_091230.xml · derivative · entry 3 LOUMEAU ERIC J · CIK 0001239648 · CHIEF LEGAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 43,000 Underlying: Common Stock · 10,000 shares Expires 2029-12-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The stock option is fully vested. F3 · balance_after: In addition to the options to purchase a total of 43,000 shares of common stock as set forth in Table II, the Reporting Person also holds additional options to purchase up to an aggregate of 414,810 shares of common stock, which options vest according to their terms. Read SEC document |
| December 22, 2025 Filed Dec 23, 2025 16:27 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | SaleCommon Stock | 10,000 | $51.00 | $510,000.00 |
DisclosureSEC source: 0001239648-25-000006 · form4-12232025_091230.xml · nonDerivative · entry 2 LOUMEAU ERIC J · CIK 0001239648 · CHIEF LEGAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,947 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person dated April 11, 2025. Read SEC document |
| December 22, 2025 Filed Dec 23, 2025 16:27 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | Exercise / conversionCommon Stock | 10,000 | $14.02 | $140,200.00 |
DisclosureSEC source: 0001239648-25-000006 · form4-12232025_091230.xml · nonDerivative · entry 1 LOUMEAU ERIC J · CIK 0001239648 · CHIEF LEGAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,947 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 18, 2025 Filed Dec 18, 2025 16:14 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | SaleCommon Stock | 141 | $46.99 | $6,625.59 |
DisclosureSEC source: 0001239648-25-000005 · form4-12182025_091200.xml · nonDerivative · entry 7 LOUMEAU ERIC J · CIK 0001239648 · CHIEF LEGAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,947 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person dated April 11, 2025. Read SEC document |
| December 17, 2025 Filed Dec 18, 2025 16:14 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $14.02 | $0.00 |
DisclosureSEC source: 0001239648-25-000005 · form4-12182025_091200.xml · derivative · entry 10 LOUMEAU ERIC J · CIK 0001239648 · CHIEF LEGAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 53,000 Underlying: Common Stock · 10,000 shares Expires 2029-12-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The stock option is fully vested. F5 · balance_after: In addition to the options to purchase a total of 53,000 shares of common stock as set forth in Table II, the Reporting Person also holds additional options to purchase up to an aggregate of 414,810 shares of common stock, which options vest according to their terms. Read SEC document |
| December 17, 2025 Filed Dec 18, 2025 16:14 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | SaleCommon Stock | 10,000 | $46.00 | $460,000.00 |
DisclosureSEC source: 0001239648-25-000005 · form4-12182025_091200.xml · nonDerivative · entry 6 LOUMEAU ERIC J · CIK 0001239648 · CHIEF LEGAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 9,088 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person dated April 11, 2025. Read SEC document |
| December 17, 2025 Filed Dec 18, 2025 16:14 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | Exercise / conversionCommon Stock | 10,000 | $14.02 | $140,200.00 |
DisclosureSEC source: 0001239648-25-000005 · form4-12182025_091200.xml · nonDerivative · entry 5 LOUMEAU ERIC J · CIK 0001239648 · CHIEF LEGAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 19,088 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 16, 2025 Filed Dec 18, 2025 16:14 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 7,500 | $0.00 Strike: $20.16 | $0.00 |
DisclosureSEC source: 0001239648-25-000005 · form4-12182025_091200.xml · derivative · entry 9 LOUMEAU ERIC J · CIK 0001239648 · CHIEF LEGAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,500 shares Expires 2030-07-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The stock option is fully vested. Read SEC document |
| December 16, 2025 Filed Dec 18, 2025 16:14 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $14.02 | $0.00 |
DisclosureSEC source: 0001239648-25-000005 · form4-12182025_091200.xml · derivative · entry 8 LOUMEAU ERIC J · CIK 0001239648 · CHIEF LEGAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 63,000 Underlying: Common Stock · 5,000 shares Expires 2029-12-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The stock option is fully vested. Read SEC document |
| December 16, 2025 Filed Dec 18, 2025 16:14 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | SaleCommon Stock | 4,195 | $45.24 | $189,768.80 |
DisclosureSEC source: 0001239648-25-000005 · form4-12182025_091200.xml · nonDerivative · entry 4 LOUMEAU ERIC J · CIK 0001239648 · CHIEF LEGAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 9,088 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person dated April 11, 2025. F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.13 to $45.34 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 16, 2025 Filed Dec 18, 2025 16:14 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | SaleCommon Stock | 8,305 | $44.68 | $371,030.86 |
DisclosureSEC source: 0001239648-25-000005 · form4-12182025_091200.xml · nonDerivative · entry 3 LOUMEAU ERIC J · CIK 0001239648 · CHIEF LEGAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 13,283 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person dated April 11, 2025. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.12 to $45.11 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 16, 2025 Filed Dec 18, 2025 16:14 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | Exercise / conversionCommon Stock | 7,500 | $20.16 | $151,200.00 |
DisclosureSEC source: 0001239648-25-000005 · form4-12182025_091200.xml · nonDerivative · entry 2 LOUMEAU ERIC J · CIK 0001239648 · CHIEF LEGAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 21,588 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 16, 2025 Filed Dec 18, 2025 16:14 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | Exercise / conversionCommon Stock | 5,000 | $14.02 | $70,100.00 |
DisclosureSEC source: 0001239648-25-000005 · form4-12182025_091200.xml · nonDerivative · entry 1 LOUMEAU ERIC J · CIK 0001239648 · CHIEF LEGAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 14,088 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 30, 2025 Filed Oct 1, 2025 16:00 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $14.02 | $0.00 |
DisclosureSEC source: 0001239648-25-000004 · form4-10012025_081017.xml · derivative · entry 3 LOUMEAU ERIC J · CIK 0001239648 · CHIEF LEGAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 68,000 Underlying: Common Stock · 5,000 shares Expires 2029-12-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The stock option vested and is exercisable as to 25% of the shares subject to the option on December 6, 2020, and thereafter vests as to 1/48th of the shares in equal monthly installments, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date. F4 · balance_after: In addition to the remaining options to purchase 68,000 shares of common stock as set forth in Table II, the Reporting Person also holds additional options to purchase up to an aggregate of 422,310 shares of common stock, which options vest according to their terms. Read SEC document |
| September 30, 2025 Filed Oct 1, 2025 16:00 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | SaleCommon Stock | 8,240 | $29.00 | $238,960.00 |
DisclosureSEC source: 0001239648-25-000004 · form4-10012025_081017.xml · nonDerivative · entry 2 LOUMEAU ERIC J · CIK 0001239648 · CHIEF LEGAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 9,088 F2 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person dated April 11, 2025. Read SEC document |
| September 30, 2025 Filed Oct 1, 2025 16:00 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | Exercise / conversionCommon Stock | 5,000 | $14.02 | $70,100.00 |
DisclosureSEC source: 0001239648-25-000004 · form4-10012025_081017.xml · nonDerivative · entry 1 LOUMEAU ERIC J · CIK 0001239648 · CHIEF LEGAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,328 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes the acquisition of 1,325 shares acquired under the Company's ESPP. Read SEC document |
| January 07, 2025 Filed Jan 7, 2025 17:32 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | GrantStock Option (right to buy) · Derivative | 67,000 | $0.00 Strike: $14.83 | $0.00 |
DisclosureSEC source: 0001415889-25-001042 · form4-01072025_100105.xml · derivative · entry 8 LOUMEAU ERIC J · CIK 0001239648 · CHIEF LEGAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 67,000 Underlying: Common Stock · 67,000 shares Expires 2035-01-06 F8 · derivative.exercise_date: The stock option vests as to 25% of the total shares on January 7, 2026, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| January 07, 2025 Filed Jan 7, 2025 17:32 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | GrantRestricted Stock Unit · Derivative | 23,550 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-001042 · form4-01072025_100105.xml · derivative · entry 7 LOUMEAU ERIC J · CIK 0001239648 · CHIEF LEGAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,550 Underlying: Common Stock · 23,550 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration. F7 · derivative.exercise_date: The RSUs vests as to 25% of the total RSUs annually commencing on January 7, 2026 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. F7 · derivative.expiration_date: The RSUs vests as to 25% of the total RSUs annually commencing on January 7, 2026 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| January 06, 2025 Filed Jan 7, 2025 17:32 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | Exercise / conversionRestricted Stock Unit · Derivative | 5,545 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-001042 · form4-01072025_100105.xml · derivative · entry 6 LOUMEAU ERIC J · CIK 0001239648 · CHIEF LEGAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,090 Underlying: Common Stock · 5,545 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration. F6 · derivative.exercise_date: The RSUs vests as to 25% of the total RSUs annually commencing on January 6, 2024 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. F6 · derivative.expiration_date: The RSUs vests as to 25% of the total RSUs annually commencing on January 6, 2024 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| January 06, 2025 Filed Jan 7, 2025 17:32 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | Tax withholdingCommon Stock | 2,217 | $15.30 | $33,920.10 |
DisclosureSEC source: 0001415889-25-001042 · form4-01072025_100105.xml · nonDerivative · entry 4 LOUMEAU ERIC J · CIK 0001239648 · CHIEF LEGAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,003 F3 · shares: Represents shares withheld by the Issuer to satisfy a portion of the tax withholding obligation in connection with the vesting of RSUs and do not represent discretionary transactions by the Reporting Person. Following the transactions reflecting in this Form 4, no additional transactions are expected to satisfy the Reporting Person's tax withholding obligation. F4 · shares: The Reporting Person did not sell or otherwise dispose of any of the shares with respect to the vesting of RSUs reported on this Form 4 for any reason other than to cover required taxes. Read SEC document |
| January 06, 2025 Filed Jan 7, 2025 17:32 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | Exercise / conversionCommon Stock | 5,545 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-25-001042 · form4-01072025_100105.xml · nonDerivative · entry 3 LOUMEAU ERIC J · CIK 0001239648 · CHIEF LEGAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,220 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration. Read SEC document |
| January 03, 2025 Filed Jan 7, 2025 17:32 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | Exercise / conversionRestricted Stock Unit · Derivative | 7,288 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-001042 · form4-01072025_100105.xml · derivative · entry 5 LOUMEAU ERIC J · CIK 0001239648 · CHIEF LEGAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,862 Underlying: Common Stock · 7,288 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration. F5 · derivative.exercise_date: The RSUs vests as to 25% of the total RSUs annually commencing on January 3, 2025 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. F5 · derivative.expiration_date: The RSUs vests as to 25% of the total RSUs annually commencing on January 3, 2025 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| January 03, 2025 Filed Jan 7, 2025 17:32 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | Tax withholdingCommon Stock | 2,994 | $14.60 | $43,712.40 |
DisclosureSEC source: 0001415889-25-001042 · form4-01072025_100105.xml · nonDerivative · entry 2 LOUMEAU ERIC J · CIK 0001239648 · CHIEF LEGAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,675 F3 · shares: Represents shares withheld by the Issuer to satisfy a portion of the tax withholding obligation in connection with the vesting of RSUs and do not represent discretionary transactions by the Reporting Person. Following the transactions reflecting in this Form 4, no additional transactions are expected to satisfy the Reporting Person's tax withholding obligation. F4 · shares: The Reporting Person did not sell or otherwise dispose of any of the shares with respect to the vesting of RSUs reported on this Form 4 for any reason other than to cover required taxes. Read SEC document |
| January 03, 2025 Filed Jan 7, 2025 17:32 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | Exercise / conversionCommon Stock | 7,288 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-25-001042 · form4-01072025_100105.xml · nonDerivative · entry 1 LOUMEAU ERIC J · CIK 0001239648 · CHIEF LEGAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,669 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration. F2 · balance_after: Reflects the acquisition of 141 shares acquired under the Company's ESPP. Read SEC document |
| September 17, 2024 Filed Sep 17, 2024 18:44 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | SaleCommon Stock | 3,780 | $38.41 | $145,190.93 |
DisclosureSEC source: 0001415889-24-023551 · form4-09172024_100920.xml · nonDerivative · entry 5 LOUMEAU ERIC J · CIK 0001239648 · CHIEF LEGAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,240 F4 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person dated June 10, 2024. F5 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.05 to $38.98 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 16, 2024 Filed Sep 17, 2024 18:44 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $14.02 | $0.00 |
DisclosureSEC source: 0001415889-24-023551 · form4-09172024_100920.xml · derivative · entry 7 LOUMEAU ERIC J · CIK 0001239648 · CHIEF LEGAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 73,000 Underlying: Common Stock · 5,000 shares Expires 2029-12-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: The stock option vested and is exercisable as to 25% of the shares subject to the option on December 6, 2020, and thereafter vests as to 1/48th of the shares in equal monthly installments, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date. F8 · balance_after: In addition to the remaining options to purchase 73,000 shares of common stock as set forth in Table II, the Reporting Person also holds additional options to purchase up to an aggregate of 355,310 shares of common stock, which options vest according to their terms. Read SEC document |
| September 16, 2024 Filed Sep 17, 2024 18:44 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | SaleCommon Stock | 6,500 | $40.13 | $260,845.00 |
DisclosureSEC source: 0001415889-24-023551 · form4-09172024_100920.xml · nonDerivative · entry 4 LOUMEAU ERIC J · CIK 0001239648 · CHIEF LEGAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,020 F4 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person dated June 10, 2024. Read SEC document |
| September 16, 2024 Filed Sep 17, 2024 18:44 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | Exercise / conversionCommon Stock | 5,000 | $14.02 | $70,100.00 |
DisclosureSEC source: 0001415889-24-023551 · form4-09172024_100920.xml · nonDerivative · entry 3 LOUMEAU ERIC J · CIK 0001239648 · CHIEF LEGAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 13,520 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 16, 2024 Filed Sep 17, 2024 18:44 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | SaleCommon Stock | 2,220 | $38.93 | $86,424.60 |
DisclosureSEC source: 0001415889-24-023551 · form4-09172024_100920.xml · nonDerivative · entry 2 LOUMEAU ERIC J · CIK 0001239648 · CHIEF LEGAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,520 F3 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. Read SEC document |
| September 14, 2024 Filed Sep 17, 2024 18:44 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | Exercise / conversionRestricted Stock Unit · Derivative | 6,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-023551 · form4-09172024_100920.xml · derivative · entry 6 LOUMEAU ERIC J · CIK 0001239648 · CHIEF LEGAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock award ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration. F6 · derivative.exercise_date: 50% of the total restricted stock units vested on September 14, 2023 and September 14, 2024, subject to the Reporting Person's provision of service to the Issuer on each vesting date. F6 · derivative.expiration_date: 50% of the total restricted stock units vested on September 14, 2023 and September 14, 2024, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| September 14, 2024 Filed Sep 17, 2024 18:44 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | Exercise / conversionCommon Stock | 6,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-023551 · form4-09172024_100920.xml · nonDerivative · entry 1 LOUMEAU ERIC J · CIK 0001239648 · CHIEF LEGAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,740 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock award ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration. F2 · balance_after: Includes 1,500 shares acquired under the Employee Stock Purchase Plan as of May 15, 2024. Read SEC document |
| July 22, 2024 Filed Jul 24, 2024 16:13 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | GrantCommon Stock · Derivative | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-020031 · form4-07242024_080748.xml · derivative · entry 1 LOUMEAU ERIC J · CIK 0001239648 · CHIEF LEGAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires not disclosed F1 · derivative.exercise_price: Each performance stock unit ("PSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration. F2 · derivative.exercise_date: Shares earned upon the vesting of a percentage of the PSUs granted to the Reporting Person on July 22, 2024. Each PSU represents a contingent right to receive one share of Issuer common stock upon the Issuer's achievement of certain share price metrics ("Performance Metrics"). 50% of the total number of shares subject to the PSU that achieves the applicable Performance Metrics shall vest on the later of (i) the 1-year anniversary of the achievement of such applicable Performance Metrics and (ii) on July 1, 2026. An additional 50% of the total number of shares subject to the PSU that achieves the applicable Performance Metrics shall vest on the 2-year anniversary of such achievement (but not later than July 1, 2028), subject to the Reporting Person' service to the Issue on each vesting date. F2 · derivative.expiration_date: Shares earned upon the vesting of a percentage of the PSUs granted to the Reporting Person on July 22, 2024. Each PSU represents a contingent right to receive one share of Issuer common stock upon the Issuer's achievement of certain share price metrics ("Performance Metrics"). 50% of the total number of shares subject to the PSU that achieves the applicable Performance Metrics shall vest on the later of (i) the 1-year anniversary of the achievement of such applicable Performance Metrics and (ii) on July 1, 2026. An additional 50% of the total number of shares subject to the PSU that achieves the applicable Performance Metrics shall vest on the 2-year anniversary of such achievement (but not later than July 1, 2028), subject to the Reporting Person' service to the Issue on each vesting date. Read SEC document |
| February 16, 2024 Filed Feb 21, 2024 17:38 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $14.02 | $0.00 |
DisclosureSEC source: 0001415889-24-004666 · form4-02212024_100259.xml · derivative · entry 3 LOUMEAU ERIC J · CIK 0001239648 · CHIEF LEGAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 78,000 Underlying: Common Stock · 5,000 shares Expires 2029-12-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The stock option vested and is exercisable as to 25% of the shares subject to the option on December 6, 2020, and thereafter vests as to 1/48th of the shares in equal monthly installments, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date. F3 · balance_after: In addition to the remaining options to purchase 78,000 shares of common stock as set forth in Table II, the Reporting Person also holds additional options to purchase up to an aggregate of 355,310 shares of common stock, which options vest according to their terms. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.